Drotaverine
| 220px | |
| Drotaverine
| |
| Systematic (IUPAC) name | |
| (1Z)-1-[(3,4-diethoxyphenyl)methylidene]-6,7- diethoxy-3,4-dihydro-2H-isoquinoline | |
| Identifiers | |
| CAS number | |
| ATC code | A03 |
| PubChem | |
| Chemical data | |
| Formula | C24H31NO4 |
| Mol. mass | 397.507 g/mol |
| Pharmacokinetic data | |
| Bioavailability | Highly variable |
| Protein binding | 80 to 95% |
| Metabolism | Hepatic |
| Half life | 7 to 12 hours |
| Excretion | Fecal and renal |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral, intravenous |
Drotaverine (INN, also known as drotaverin) is an antispasmodic drug, structurally related to papaverine. Drotaverine is a selective inhibitor of phosphodiesterase 4, and has no anticholinergic effects.
A small 2003 study found drotaverine to be nearly 80% effective in treating renal colic.[1] It has also been used to accelerate labor.[2]
References
- ↑ Romics I, Molnár DL, Timberg G; et al. (2003). "The effect of drotaverine hydrochloride in acute colicky pain caused by renal and ureteric stones". BJU Int. 92 (1): 92–6. PMID 12823389. doi:10.1046/j.1464-410X.2003.04262.x.
- ↑ Singh KC, Jain P, Goel N, Saxena A (2004). "Drotaverine hydrochloride for augmentation of labor". Int J Gynaecol Obstet. 84 (1): 17–22. PMID 14698825.
